CAS: 2101765-81-3

Dri-c21045 inhibits NF-kB (IC50=17.1μM) and B cell proliferation (IC50=4.5μM), selectively blocking CD40-CD40L interaction (IC50=0.17μM).

DRI-c21045 is an analog of a medicinal compound that has been shown to inhibit the activity of a specific protein kinase involved in cell cycle regulation and tumor growth. This inhibitor has been demonstrated to induce apoptosis in cancer cells, making it a promising candidate for anticancer therapy. DRI-c21045 has been tested in both Chinese and human cancer cell lines and has shown potent activity against various types of tumors. Additionally, this compound has been detected in urine samples from patients with cancer, suggesting that it may have potential as a diagnostic marker for certain types of cancer. Overall, DRI-c21045 shows great promise as a potential anticancer agent with significant therapeutic potential.

DRI-C21045